Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway
US12287338B2 · kind B2 · utility
0Cited by
2References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 27, 2020 |
| Grant date | Apr 29, 2025 |
| Priority date | — |
| Expiry date | Dec 26, 2042 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are biomarkers for predicting the efficacy of MDM2 inhibitor or Bcl-2/Bcl-xL dual inhibitors or Bcl-2 inhibitor or Bcl-xL inhibitor in treating cancer patients. Also provided are compositions, e.g., kits, for evaluating gene levels of the biomarkers and methods of using such gene levels to predict a cancer patient's response to the MDM2 inhibitors or Bcl-2/Bcl-xL dual inhibitors or Bcl-2 inhibitor or Bcl-xL inhibitor. Such information can be used in determining prognosis and treatment options for cancer patients.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.